A.95 If an incentive-fee or award-fee FAR 16.404(b), type contract is being used, has the 16.301-3, required D&F been executed and 16.401(e)(3) signed by the HCA, and is compliance with FAR assured? Synopsis A.96 If no FAR exception, has FAR 5.101 FedBizOpps (FBO) notice been (>$25,000), properly published? 5.202, 5.203(a) (may be < 15 days-commercial items) A.97 If subject to Trade Agreements Act FAR 25.408 (TAA), has proper note been included in Synopsis? A.98 If CO believes that advance notice HHSAR 305.202 is not appropriate, has memo requesting relief from synopsizing been approved by HHS? Action Item FAR/HHSAR/ Yes No N/A Comments No. NIH Policy Part A.99 If brand name specifications, did FAR 6.302-1(c), CO include justification or 6.305(c), 13.501, documentation required in FBO? OFPP memo 4/17/06 A.100 If notice in GPE (i.e., FBO) is not FAR 11.105, required, is file documented re: use OFPP Memo of name specifications? 4/17/06
A.95 If an incentive-fee or award-fee type contract is being used, has the required D&F been executed and signed by the HCA, and is compliance with FAR assured? FAR 16.404(b), 16.301-3, 16.401(e)(3) Synopsis A.96 If no FAR exception, has FedBizOpps (FBO) notice been properly published? FAR 5.101 (>$25,000), 5.202, 5.203(a) (may be < 15 days-commercial items) A.97 If subject to Trade Agreements Act (TAA), has proper note been included in Synopsis? FAR 25.408 A.98 If CO believes that advance notice is not appropriate, has memo requesting relief from synopsizing been approved by HHS? HHSAR 305.202 No. Action Item FAR/HHSAR/ NIH Policy Part Yes No N/A Comments A.99 If brand name specifications, did CO include justification or documentation required in FBO? FAR 6.302-1(c), 6.305(c), 13.501, OFPP memo 4/17/06 A.100 If notice in GPE (i.e., FBO) is not required, is file documented re: use of name specifications? FAR 11.105, OFPP Memo 4/17/06
BOCARvwChcklstNegDec11_508.docx